Scholarlink

<p>The immunodeficient mouse model offers a platform for evaluating therapeutic options in preclinical cancer research by enabling the growth of human xenografts. We previously developed BALB/c Rag2<sup>null</sup>Jak3<sup>null</sup> (BRJ), an immunodeficient mouse model useful for cancer studies. However, susceptibility to xenograft acceptance can be increased through signal regulatory protein alpha (SIRPα)-CD47 signaling, also known as the “don't eat me” signal. In this study, we generated BALB/c human-SIRPα BAC transgenic mice and crossed them with BRJ mice. The resulting human SIRPα-transgenic BRJ (BRJ-S) mice showed a significantly higher engraftment rate of human B-cell lymphoma than BRJ mice. Furthermore, we demonstrated better human tumor engraftment in BRJ-S mice by reducing phagocytosis. In summary, hSIRPα-transgenic BRJ mice (BRJ-S) serve as a promising immunodeficient model with enhanced capacity for human lymphoma engraftment. BRJ-S provides an advantageous and permissive model for xenografting and for studying cancer in research and drug development.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Transgenic expression of human signal regulatory protein alpha (SIRPα) in BALB/c Rag2null/Jak3null immunodeficient mice enhances human lymphoma xenografts by reducing phagocytosis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月15日

查看全文
  • Jutatip Panaampon,
  • Tatsuya Ogawa,
  • Akira Shiota,
  • Seiji Okada

摘要

The immunodeficient mouse model offers a platform for evaluating therapeutic options in preclinical cancer research by enabling the growth of human xenografts. We previously developed BALB/c Rag2nullJak3null (BRJ), an immunodeficient mouse model useful for cancer studies. However, susceptibility to xenograft acceptance can be increased through signal regulatory protein alpha (SIRPα)-CD47 signaling, also known as the “don't eat me” signal. In this study, we generated BALB/c human-SIRPα BAC transgenic mice and crossed them with BRJ mice. The resulting human SIRPα-transgenic BRJ (BRJ-S) mice showed a significantly higher engraftment rate of human B-cell lymphoma than BRJ mice. Furthermore, we demonstrated better human tumor engraftment in BRJ-S mice by reducing phagocytosis. In summary, hSIRPα-transgenic BRJ mice (BRJ-S) serve as a promising immunodeficient model with enhanced capacity for human lymphoma engraftment. BRJ-S provides an advantageous and permissive model for xenografting and for studying cancer in research and drug development.